120 related articles for article (PubMed ID: 36725401)
1. Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial.
Salfati D; Huot M; Aparicio T; Lepage C; Taieb J; Bouché O; Boige V; Phelip JM; Dahan L; Bennouna J; Le Malicot K; Boussari O; Gornet JM
Dig Liver Dis; 2023 Jun; 55(6):791-798. PubMed ID: 36725401
[TBL] [Abstract][Full Text] [Related]
2. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
[TBL] [Abstract][Full Text] [Related]
4. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
5. CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
Kang S; Kim SY; Hong YS; Kim TW; Choi KE; Kim MJ; Kim JE
Sci Rep; 2023 Apr; 13(1):6735. PubMed ID: 37185297
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
[TBL] [Abstract][Full Text] [Related]
7. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
[TBL] [Abstract][Full Text] [Related]
8. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
[TBL] [Abstract][Full Text] [Related]
9. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
10. Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer.
Quidde J; Denne L; Kutscheidt A; Kindler M; Kirsch A; Kripp M; Petersen V; Schulze M; Seraphin J; Tummes D; Arnold D; Stein A
Oncol Res Treat; 2017; 40(1-2):21-26. PubMed ID: 28192780
[TBL] [Abstract][Full Text] [Related]
11. Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy.
Michl M; Koch J; Laubender RP; Modest DP; Giessen C; Schulz Ch; Heinemann V
Tumour Biol; 2014 Oct; 35(10):10121-7. PubMed ID: 25023402
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
[TBL] [Abstract][Full Text] [Related]
13. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer.
Cai D; Huang ZH; Yu HC; Wang XL; Bai LL; Tang GN; Peng SY; Li YJ; Huang MJ; Cao GW; Wang JP; Luo YX
World J Gastroenterol; 2019 Sep; 25(33):4945-4958. PubMed ID: 31543685
[TBL] [Abstract][Full Text] [Related]
15. CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.
Sunakawa Y; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Ichikawa W
Target Oncol; 2017 Dec; 12(6):787-794. PubMed ID: 29064002
[TBL] [Abstract][Full Text] [Related]
16. The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients.
Yu P; Zhou M; Qu J; Fu L; Li X; Cai R; Jin B; Teng Y; Liu J; Shi J; Zhang J
BMC Cancer; 2018 Nov; 18(1):1076. PubMed ID: 30404612
[TBL] [Abstract][Full Text] [Related]
17. Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA.
Gulhati P; Yin J; Pederson L; Schmoll HJ; Hoff P; Douillard JY; Hecht JR; Tournigand C; Tebbut N; Chibaudel B; Gramont A; Shi Q; Overman MJ
J Natl Cancer Inst; 2020 Nov; 112(11):1127-1136. PubMed ID: 32191317
[TBL] [Abstract][Full Text] [Related]
18. Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy.
Guo G; Chen X; Cai X; Chen Y; Wang H; Fan L; Bai L; Qiu H; Zhang B
Transl Cancer Res; 2019 Aug; 8(4):1137-1147. PubMed ID: 35116856
[TBL] [Abstract][Full Text] [Related]
19. Carcinoembryonic Antigen-related Tumor Kinetics After Eight Weeks of Chemotherapy is Independently Associated With Overall Survival in Patients With Metastatic Colorectal Cancer.
Colloca GA; Venturino A; Guarneri D
Clin Colorectal Cancer; 2020 Dec; 19(4):e200-e207. PubMed ID: 32952072
[TBL] [Abstract][Full Text] [Related]
20. Serum carcinoembryonic antigen pre-operative level in colorectal cancer: revisiting risk stratification.
Iacuzzo C; Germani P; Troian M; Cipolat Mis T; Giudici F; Osenda E; Bortul M; de Manzini N
ANZ J Surg; 2021 Jun; 91(6):E367-E374. PubMed ID: 33870621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
